WHATNEXT partner site Patient Worthy reports that the United States Food and Drug Administration has granted fast track designation to an investigational compound called CAN-2409. The potential medication is currently in development for pancreatic cancer by Candel Therapeutics.
Patient Worthy writer James Moore notes:
The results from the trial included an estimated survival rate of 71.4% at 24 months and at 36 months. Patients received either two or three doses of CAN-2409, along with a prodrug regimen and chemoradiation before undergoing surgery. The placebo group, by comparison, saw an estimated survival rate of only 16.7% in the same timeframe.
You can read more about the clinical trial and fast track designation of CAN-2409 for pancreatic cancer over at Patient Worthy.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
Last modified: February 29, 2024
